Pembrolizumab improves pCR in early triple-negative breast cancer
21 Apr 2020
byAudrey Abella
The addition of the anti-PD-1* monoclonal antibody pembrolizumab to platinum-based neoadjuvant chemotherapy (CT) led to a significant increase in the proportion of women with early triple-negative breast cancer (TNBC) who had a pathological complete response (pCR), the phase III KEYNOTE-522 trial has shown.
